These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25888926)

  • 1. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
    Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
    Biochem Pharmacol; 2015 Jun; 95(3):133-44. PubMed ID: 25888926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
    Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
    J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity.
    Griffith DM; Duff B; Suponitsky KY; Kavanagh K; Morgan MP; Egan D; Marmion CJ
    J Inorg Biochem; 2011 Jun; 105(6):793-9. PubMed ID: 21497577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.
    Novohradsky V; Zanellato I; Marzano C; Pracharova J; Kasparkova J; Gibson D; Gandin V; Osella D; Brabec V
    Sci Rep; 2017 Jun; 7(1):3751. PubMed ID: 28623355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.
    Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
    J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)].
    Brabec V; Griffith DM; Kisova A; Kostrhunova H; Zerzankova L; Marmion CJ; Kasparkova J
    Mol Pharm; 2012 Jul; 9(7):1990-9. PubMed ID: 22591133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
    Eikel D; Lampen A; Nau H
    Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells.
    Ganai SA; Kalladi SM; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
    Alessio M; Zanellato I; Bonarrigo I; Gabano E; Ravera M; Osella D
    J Inorg Biochem; 2013 Dec; 129():52-7. PubMed ID: 24080480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Anticancer Pt
    Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
    Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
    Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
    Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.
    Marchion DC; Bicaku E; Daud AI; Sullivan DM; Munster PN
    Cancer Res; 2005 May; 65(9):3815-22. PubMed ID: 15867379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
    Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
    Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
    Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
    J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z; Hu W; Wang Z; Gou S
    Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
    Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
    Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.